Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNβ-NIS) Monotherapy and in Combination With Avelumab, in Patients With Refractory Solid Tumors

NCT02923466 is registered in ClinicalTrials.gov with Vyriad, Inc. as lead sponsor.

NCT NCT02923466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02923466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNβ-NIS) Monotherapy and in Combination With Avelumab, in Patients With Refractory Solid Tumors
Lead sponsor
Vyriad, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 17, 2017
Completion date
April 22, 2022
Enrollment
76 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

malignant solid tumour